Enfusion, Inc. (NYSE:ENFN) CFO Bradley Herring Sells 4,134 Shares

Enfusion, Inc. (NYSE:ENFN) CFO Bradley Herring sold 4,134 shares of Enfusion stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $10.13, for a total value of $41,877.42. Following the transaction, the chief financial officer now owns 266,369 shares of the company’s stock, valued at $2,698,317.97. The trade was a 1.53 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Bradley Herring also recently made the following trade(s):

• On Friday, December 20th, Bradley Herring sold 24,443 shares of Enfusion stock. The shares were sold at an average price of $10.61, for a total value of $259,340.23.

Enfusion Price Performance

ENFN stock opened at $9.97 on Friday. Enfusion, Inc. has a 1-year low of $7.52 and a 1-year high of $11.38. The stock has a market capitalization of $1.28 billion, a P/E ratio of 249.31, a P/E/G ratio of 3.98 and a beta of 0.95. The business has a fifty day moving average price of $10.11 and a 200-day moving average price of $9.19.

Institutional Trading of Enfusion

Large investors have recently modified their holdings of the company. Arizona State Retirement System bought a new stake in shares of Enfusion in the second quarter worth $86,000. Harbor Capital Advisors Inc. grew its holdings in shares of Enfusion by 12.4% in the third quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock worth $113,000 after acquiring an additional 1,315 shares during the period. Belvedere Trading LLC bought a new stake in shares of Enfusion in the third quarter worth $114,000. Paloma Partners Management Co bought a new stake in shares of Enfusion in the third quarter worth $157,000. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Enfusion by 27.7% in the second quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock worth $167,000 after acquiring an additional 4,239 shares during the period. Institutional investors own 81.05% of the company’s stock.

Analyst Upgrades and Downgrades

ENFN has been the subject of a number of recent research reports. Stifel Nicolaus lifted their price objective on Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Piper Sandler boosted their price target on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a research note on Monday, December 23rd. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $10.25.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.